IGNT logo

Ingen Technologies, Inc. (IGNT) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Ingen Technologies, Inc. (IGNT), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 49/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
49/100 AI Puanı

Ingen Technologies, Inc. (IGNT) Sağlık ve Boru Hattı Genel Bakışı

CEODavid S. Hanson
MerkezRiverside, US
Halka Arz Yılı2009
SektörHealthcare

Ingen Technologies, Inc. manufactures and distributes respiratory medical devices, including oxygen flow meters and nasal cannulas, primarily serving patients with COPD. The company's focus on pneumatic metering devices and specialized nasal cannula technology positions it within a niche segment of the broader medical device market, characterized by increasing demand for home healthcare solutions.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Ingen Technologies, Inc. presents a focused investment opportunity within the respiratory medical device sector. The company's specialization in oxygen flow meters and nasal cannulas for COPD patients positions it to capitalize on the growing demand for home healthcare solutions. A key value driver is the company's proprietary Oxyview technology, which offers precise oxygen flow monitoring. However, potential investors may want to evaluate the company's negative P/E ratio of -0.05 and a significant negative profit margin of -7460.4%. While the gross margin is a high 95.7%, profitability remains a concern. Growth catalysts include expanding distribution networks and potential partnerships to reach a broader patient base. The investment thesis hinges on Ingen's ability to achieve profitability through increased sales volume and efficient cost management.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Ingen Technologies operates in the medical device industry, focusing on respiratory care products.
  • The company's primary products include oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademarks.
  • Ingen Technologies has a high gross margin of 95.7%, indicating efficient production processes.
  • The company's P/E ratio is -0.05, reflecting current losses.
  • Ingen Technologies serves patients suffering from chronic obstructive pulmonary disease (COPD).

Rakipler & Benzerleri

Güçlü Yönler

  • Specialized product line focused on respiratory care.
  • Proprietary Oxyview technology for accurate oxygen flow monitoring.
  • Established presence in the respiratory medical device market.
  • High gross margin of 95.7%.

Zayıflıklar

  • Negative P/E ratio of -0.05, indicating current losses.
  • High negative profit margin of -7460.4%.
  • Limited product diversification.
  • Dependence on the respiratory care market.

Katalizörler

  • Upcoming: Potential partnerships with home healthcare providers to expand distribution.
  • Upcoming: Development and launch of new respiratory devices.
  • Ongoing: Increasing demand for home healthcare solutions for COPD patients.
  • Ongoing: Expansion of the Oxyview product line.
  • Ongoing: Integration of devices with telehealth platforms.

Riskler

  • Potential: Competition from larger medical device manufacturers.
  • Potential: Regulatory changes affecting the medical device industry.
  • Ongoing: Economic downturn impacting healthcare spending.
  • Potential: Technological advancements rendering existing products obsolete.
  • Ongoing: The company's negative P/E ratio and high negative profit margin.

Büyüme Fırsatları

  • Expansion of Product Line: Ingen Technologies can expand its product line to include additional respiratory devices and accessories, such as nebulizers, ventilators, and sleep apnea devices. This would allow the company to cater to a broader range of respiratory conditions and increase its market share. The global market for respiratory devices is projected to reach $35 billion by 2028, providing a significant opportunity for growth. Timeline: 2-3 years.
  • Strategic Partnerships: Ingen Technologies can form strategic partnerships with home healthcare providers, hospitals, and durable medical equipment (DME) suppliers to expand its distribution network and reach a larger patient base. These partnerships can provide access to established sales channels and enhance the company's brand recognition. The market for home healthcare services is expected to grow at a rate of 8% annually, creating a favorable environment for partnerships. Timeline: 1-2 years.
  • Geographic Expansion: Ingen Technologies can expand its geographic presence beyond the United States to international markets, such as Europe and Asia, where there is a growing demand for respiratory care products. This would require obtaining regulatory approvals in each target market and establishing distribution channels. The global market for respiratory devices is expected to grow at a CAGR of 6% over the next five years, driven by increasing healthcare spending in emerging markets. Timeline: 3-5 years.
  • Telehealth Integration: Ingen Technologies can integrate its devices with telehealth platforms to enable remote patient monitoring and management. This would allow healthcare providers to track patients' oxygen levels and respiratory function remotely, improving patient outcomes and reducing healthcare costs. The telehealth market is projected to reach $175 billion by 2026, creating a significant opportunity for Ingen Technologies to leverage its technology. Timeline: 1-2 years.
  • Focus on Innovation: Ingen Technologies can invest in research and development to develop innovative respiratory devices and technologies that address unmet needs in the market. This could include developing more advanced oxygen delivery systems, wearable respiratory sensors, and AI-powered respiratory monitoring tools. The market for innovative medical devices is growing rapidly, driven by increasing demand for personalized and data-driven healthcare solutions. Timeline: Ongoing.

Fırsatlar

  • Expansion of product line to include additional respiratory devices.
  • Strategic partnerships with home healthcare providers and DME suppliers.
  • Geographic expansion to international markets.
  • Integration of devices with telehealth platforms.

Tehditler

  • Competition from larger medical device manufacturers.
  • Regulatory changes affecting the medical device industry.
  • Economic downturn impacting healthcare spending.
  • Technological advancements rendering existing products obsolete.

Rekabet Avantajları

  • Specialized product line focused on respiratory care.
  • Proprietary Oxyview technology for accurate oxygen flow monitoring.
  • Established presence in the respiratory medical device market.
  • Brand recognition for Oxyview and Smart Nasal Cannula products.

IGNT Hakkında

Founded in 1999 and based in Riverside, California, Ingen Technologies, Inc. operates as a medical device manufacturing company focused on the respiratory industry. The company develops, manufactures, and markets medical equipment designed for patients suffering from chronic obstructive pulmonary disease (COPD). Ingen's core product offerings include oxygen flow meters and nasal cannulas, marketed under the Oxyview and Smart Nasal Cannula trademarks. The Oxyview device is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient, ensuring accurate and reliable oxygen delivery. The Smart Nasal Cannula is designed to enhance patient comfort and improve oxygen delivery efficiency. Ingen Technologies targets the home healthcare market, providing solutions that enable patients to manage their respiratory conditions effectively outside of a hospital setting. The company's focus on specialized respiratory devices differentiates it from larger medical device manufacturers with broader product portfolios. Ingen Technologies distributes its products primarily within the United States.

Ne Yaparlar

  • Manufactures medical devices for the respiratory industry.
  • Produces medical equipment for patients with chronic obstructive pulmonary disease (COPD).
  • Offers oxygen flow meters under the Oxyview trademark.
  • Provides nasal cannulas under the Smart Nasal Cannula trademark.
  • Develops pneumatic metering devices to display and confirm oxygen flow rates.
  • Focuses on improving oxygen delivery and patient comfort.

İş Modeli

  • Manufactures and sells oxygen flow meters and nasal cannulas.
  • Targets patients with chronic obstructive pulmonary disease (COPD).
  • Distributes products through medical equipment suppliers and healthcare providers.
  • Generates revenue from the sale of its medical devices.

Sektör Bağlamı

Ingen Technologies operates within the medical device industry, specifically targeting the respiratory care segment. This segment is driven by the increasing prevalence of respiratory diseases such as COPD, and the growing demand for home healthcare solutions. The market is competitive, with established players like AFIB (Acutus Medical, Inc.) and ALST (Allstar Healthcare, Inc.) offering a range of respiratory devices. Ingen Technologies differentiates itself through its focus on specialized oxygen delivery and monitoring devices. The industry is subject to regulatory oversight, requiring companies to obtain approvals for their products. Market trends include the adoption of telehealth and remote patient monitoring, which could create opportunities for Ingen Technologies to integrate its devices with digital health platforms.

Kilit Müşteriler

  • Patients suffering from chronic obstructive pulmonary disease (COPD).
  • Hospitals and clinics providing respiratory care.
  • Home healthcare providers.
  • Durable medical equipment (DME) suppliers.
AI Güveni: 71% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Ingen Technologies, Inc. (IGNT) hisse senedi fiyatı: Price data unavailable

Son Haberler

IGNT için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

IGNT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

IGNT için Wall Street fiyat hedefi analizi.

MoonshotScore

49/100

Bu puan ne anlama geliyor?

MoonshotScore, IGNT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: David S. Hanson

CEO

David S. Hanson is the Chief Executive Officer of Ingen Technologies, Inc. His background includes experience in the medical device industry, with a focus on product development and marketing. He has been involved in the development and commercialization of several respiratory care products. His expertise lies in identifying market needs and developing innovative solutions to address them. He has a strong understanding of the regulatory landscape and the challenges of bringing new medical devices to market.

Sicil: Under David S. Hanson's leadership, Ingen Technologies, Inc. has focused on expanding its product line and distribution network. Key milestones include the development and launch of the Smart Nasal Cannula and the expansion of the Oxyview product line. He has focused on improving the company's operational efficiency and reducing costs. However, the company's profitability remains a challenge.

IGNT OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Ingen Technologies, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet the requirements of higher tiers. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for IGNT is likely very limited given its OTC Other listing and small market capitalization. Expect wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. The low trading volume can lead to significant price fluctuations, especially on news or rumors. Executing large trades may be challenging or impossible without significantly impacting the market price. Investors should be prepared for potential delays in order execution and the risk of not being able to sell shares quickly if needed.
OTC Risk Faktörleri:
  • Limited Financial Disclosure: The Unknown disclosure status makes it difficult to assess the company's financial health.
  • Low Liquidity: The OTC Other listing and small market cap suggest limited trading volume and wide bid-ask spreads.
  • Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight than exchange-listed companies.
  • Going Concern Risk: Companies on the OTC Other tier may face financial difficulties or be at risk of bankruptcy.
  • Price Volatility: Low trading volume can lead to significant price fluctuations.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the background and experience of the company's management team.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's revenue and profitability trends.
  • Check for any legal or regulatory issues involving the company.
  • Monitor the company's trading volume and price volatility.
  • Consult with a financial advisor before investing.
Meşruiyet Sinyalleri:
  • The company has been in operation since 1999.
  • The company manufactures and sells medical devices.
  • The company has trademarks for its Oxyview and Smart Nasal Cannula products.
  • The company has a CEO, David S. Hanson.
  • The company is based in the United States.

IGNT Healthcare Hisse Senedi SSS

IGNT için değerlendirilmesi gereken temel faktörler nelerdir?

Ingen Technologies, Inc. (IGNT) şu anda yapay zeka skoru 49/100, düşük puanı gösteriyor. Temel güçlü yan: Specialized product line focused on respiratory care.. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device manufacturers.. Bu bir finansal tavsiye değildir.

IGNT MoonshotScore'u nedir?

IGNT şu anda MoonshotScore'da 49/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

IGNT verileri ne sıklıkla güncellenir?

IGNT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler IGNT hakkında ne diyor?

IGNT için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

IGNT'a yatırım yapmanın riskleri nelerdir?

IGNT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device manufacturers.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

IGNT'ın P/E oranı nedir?

IGNT için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için IGNT'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

IGNT aşırı değerli mi, yoksa düşük değerli mi?

Ingen Technologies, Inc. (IGNT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

IGNT'ın temettü verimi nedir?

Ingen Technologies, Inc. (IGNT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data is based on the latest available information.
  • OTC market data may be limited or unreliable.
  • AI analysis is pending and may provide further insights.
Veri Kaynakları

Popüler Hisseler